Tel.: +33 (0)9 72 56 94 99

Inoviem Scientific presents the results of a transversal clinical study using PIMS® technology at the Falk Symposium. London.

In collaboration with Erlangen and Ingolstadt hospitals, Inoviem Scientific has realized a transversal study for the prediction of response to anti-TNF therapy with 47 patients suffering from IBD, using its cutting-edge technology, PIMS®.

Results of this transversal study have been presented to the Falk International Symposium and Inoviem Scientific have been awared the best oral presentation.